[go: up one dir, main page]

MX2017007069A - Composiciones con inhibidor selectivo de la trans-señalizacion de il-6. - Google Patents

Composiciones con inhibidor selectivo de la trans-señalizacion de il-6.

Info

Publication number
MX2017007069A
MX2017007069A MX2017007069A MX2017007069A MX2017007069A MX 2017007069 A MX2017007069 A MX 2017007069A MX 2017007069 A MX2017007069 A MX 2017007069A MX 2017007069 A MX2017007069 A MX 2017007069A MX 2017007069 A MX2017007069 A MX 2017007069A
Authority
MX
Mexico
Prior art keywords
trans
selective
inhibitor compositions
signalling inhibitor
signalling
Prior art date
Application number
MX2017007069A
Other languages
English (en)
Other versions
MX388268B (es
Inventor
Cottingham Ian
Plaksin Daniel
Duboeuf Jérémy
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of MX2017007069A publication Critical patent/MX2017007069A/es
Publication of MX388268B publication Critical patent/MX388268B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)

Abstract

Un inhibidor selectivo de la trans-señalización de IL-6 se puede usar para tratar una variedad de condiciones mediadas por la IL-6, entre ellas, enfermedades inflamatorias y cáncer. El inhibidor se puede administrar de forma segura a los seres humanos en una variedad de dosis.
MX2017007069A 2014-12-01 2015-12-01 Composiciones con inhibidor selectivo de la trans-señalizacion de il-6. MX388268B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14195726 2014-12-01
PCT/NL2015/050837 WO2016089206A2 (en) 2014-12-01 2015-12-01 Selective il-6-trans-signalling inhibitor compositions

Publications (2)

Publication Number Publication Date
MX2017007069A true MX2017007069A (es) 2018-02-09
MX388268B MX388268B (es) 2025-03-18

Family

ID=52000745

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017007069A MX388268B (es) 2014-12-01 2015-12-01 Composiciones con inhibidor selectivo de la trans-señalizacion de il-6.
MX2021007899A MX2021007899A (es) 2014-12-01 2017-06-05 Composiciones con inhibidor selectivo de la trans-se?alizacion de il-6.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021007899A MX2021007899A (es) 2014-12-01 2017-06-05 Composiciones con inhibidor selectivo de la trans-se?alizacion de il-6.

Country Status (20)

Country Link
US (3) US10519218B2 (es)
EP (2) EP3227325B1 (es)
JP (2) JP6827941B2 (es)
KR (2) KR20240131465A (es)
CN (1) CN107406491A (es)
CA (1) CA2969314A1 (es)
DK (1) DK3227325T3 (es)
ES (1) ES2981475T3 (es)
FI (1) FI3227325T3 (es)
HR (1) HRP20240581T1 (es)
HU (1) HUE066987T2 (es)
LT (1) LT3227325T (es)
MA (1) MA41116B1 (es)
MD (1) MD3227325T2 (es)
MX (2) MX388268B (es)
PL (1) PL3227325T3 (es)
PT (1) PT3227325T (es)
RS (1) RS65665B1 (es)
SI (1) SI3227325T1 (es)
WO (1) WO2016089206A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3227325T3 (fi) * 2014-12-01 2024-07-10 Ferring Bv Selektiivisiä il-6-trans-signaloinnin estäjäkoostumuksia
MD3226888T2 (ro) 2014-12-01 2021-08-31 Ferring Bv Administrarea unui inhibitor de trans-semnalizare a IL-6 selectiv
CA3080656A1 (en) 2017-10-30 2019-05-09 Baxalta GmbH Environmentally compatible detergents for inactivation of lipid-enveloped viruses
AU2018374232A1 (en) * 2017-11-30 2020-07-23 Bio-Thera Solutions, Ltd. Liquid preparation of humanized antibody for treating IL-6-related disease
US11845952B2 (en) * 2018-02-07 2023-12-19 Nippon Medical School Foundation Adeno-associated virus vector
BR112022025166A2 (pt) * 2020-06-10 2022-12-27 Ferring Bv Composto farmacêutico para o tratamento de doença cardiovascular aterosclerótica
WO2022139580A1 (en) 2020-12-22 2022-06-30 Ferring B.V. Blood gene expression biomarkers to predict response in patients with inflammatory bowel diseases
CN114681592A (zh) * 2020-12-31 2022-07-01 天境生物科技(杭州)有限公司 包含可溶性gp130二聚体的制剂和使用方法
WO2024011946A1 (en) * 2022-07-12 2024-01-18 I-Mab Biopharma (Hangzhou) Co., Ltd Polypeptide dimers for the treatment of systemic sclerosis

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
JPH04218000A (ja) 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
WO1994012520A1 (en) 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US5783672A (en) 1994-05-26 1998-07-21 Immunex Corporation Receptor for oncostatin M
US6472179B2 (en) 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
DE19941897B4 (de) 1999-09-02 2006-06-14 GSF - Forschungszentrum für Umwelt und Gesundheit GmbH IL-6 Rezeptor-Protein, Beta-Kette (gp130) des IL-6 Rezeptor-Proteins, für diese Proteine kodierende DNA, davon abgeleitete RNA, Peptid mit den Aminosäuren 771-811 dieser Beta-Kette oder Teilen davon und deren Verwendungen
WO2001058957A2 (en) 2000-02-11 2001-08-16 Lexigen Pharmaceuticals Corp. Enhancing the circulating half-life of antibody-based fusion proteins
SI1148065T1 (sl) 2000-04-21 2008-06-30 Conaris Res Inst Ag FUZIJSKI PROTEINI, KI VSEBUJEJO DVE TOPNI MOLEKULI gp130.
MY137181A (en) 2001-05-21 2009-01-30 Nektar Therapeutics Pulmonary administration of chemically modified insulin
AU2002333241B2 (en) 2001-07-18 2008-09-18 Merck Patent Gmbh Glycoprotein VI fusion proteins
US6887687B2 (en) 2001-07-30 2005-05-03 Immunex Corporation Nucleic acids encoding human ataxin-1-like polypeptide IMX97018
JP2004182638A (ja) 2002-12-03 2004-07-02 Yakult Honsha Co Ltd 炎症性疾患又は悪性腫瘍の予防治療剤
EP1491554A1 (en) 2003-06-23 2004-12-29 CONARIS research institute AG PEGylated soluble gp130-dimers useful as a medicament
ATE399868T1 (de) 2004-08-27 2008-07-15 Conaris Res Inst Ag Optimierte nukleotidsequenzen die für sgp130 kodieren
EP1801121A1 (en) 2005-12-23 2007-06-27 CONARIS research institute AG Soluble gp130 molecule variants useful as a medicament
DK1966244T3 (da) * 2005-12-30 2012-04-23 Merck Patent Gmbh Anti-il-6-antistoffer der forebygger bindingen af il-6 sammensat af il-6ralfa til gp130
KR20140107702A (ko) * 2006-06-30 2014-09-04 코나리스 리써치 인스티튜트 아게 개선된 ｓｇｐ130Ｆｃ 이량체
PT1873166E (pt) * 2006-06-30 2010-12-09 Conaris Res Inst Ag Dímeros de sgp130fc melhorados
EP2050759A1 (en) * 2007-10-19 2009-04-22 CONARIS research institute AG Soluble gp 130 muteins with improved binding activity
DK2661492T3 (en) * 2011-01-06 2018-01-15 Univ Johns Hopkins Method for Preparing Recombinant Glycoproteins with Increased Circuit Half Life in Mammalian Cells
FI3227325T3 (fi) * 2014-12-01 2024-07-10 Ferring Bv Selektiivisiä il-6-trans-signaloinnin estäjäkoostumuksia
MD3226888T2 (ro) * 2014-12-01 2021-08-31 Ferring Bv Administrarea unui inhibitor de trans-semnalizare a IL-6 selectiv

Also Published As

Publication number Publication date
PL3227325T3 (pl) 2024-10-07
HUE066987T2 (hu) 2024-09-28
PT3227325T (pt) 2024-07-01
US20180282396A1 (en) 2018-10-04
CN107406491A (zh) 2017-11-28
DK3227325T3 (da) 2024-07-08
RS65665B1 (sr) 2024-07-31
MA41116A (fr) 2017-10-10
US11306136B2 (en) 2022-04-19
ES2981475T3 (es) 2024-10-09
MD3227325T2 (ro) 2024-09-30
SI3227325T1 (sl) 2024-06-28
JP6827941B2 (ja) 2021-02-10
KR102699098B1 (ko) 2024-08-27
WO2016089206A2 (en) 2016-06-09
JP2021073229A (ja) 2021-05-13
EP4356962A2 (en) 2024-04-24
HRP20240581T1 (hr) 2024-07-19
KR20240131465A (ko) 2024-08-30
US20220275056A1 (en) 2022-09-01
US10519218B2 (en) 2019-12-31
JP7184936B2 (ja) 2022-12-06
MX388268B (es) 2025-03-18
FI3227325T3 (fi) 2024-07-10
MX2021007899A (es) 2021-09-08
KR20170135818A (ko) 2017-12-08
EP4356962A3 (en) 2024-07-24
EP3227325A2 (en) 2017-10-11
JP2017536848A (ja) 2017-12-14
MA41116B1 (fr) 2024-07-31
CA2969314A1 (en) 2016-06-09
US20200123226A1 (en) 2020-04-23
EP3227325B1 (en) 2024-04-10
LT3227325T (lt) 2024-05-27
WO2016089206A3 (en) 2016-07-28

Similar Documents

Publication Publication Date Title
ZA202004557B (en) Modulatory polynucleotides
MX2021007899A (es) Composiciones con inhibidor selectivo de la trans-se?alizacion de il-6.
NZ724691A (en) Quinoline derivatives as smo inhibitors
MX2020009780A (es) Compuestos de inhibidor de autotaxina.
MX378145B (es) Formulaciones farmacéuticas tópicas que comprenden crisaborol para tratar afecciones inflamatorias
EA201691582A1 (ru) Новые фармацевтические препараты
MX2017014191A (es) Metodos de tratamiento de una enfermedad neurodegenerativa.
MX378435B (es) Administración específica del sitio de un inhibidor de btk.
MX2020001756A (es) Compuestos deuterados del inhibidor vmat y el uso de dichos compuestos.
EA201691481A1 (ru) ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ
PH12016502291A1 (en) Indolizine derivatives as phosphoinositide 3-kinases inhibitors
EA202091731A1 (ru) Ингибиторы аутотаксина и их применения
TW201713333A (en) Methods of treating a neurodegenerative disease
PH12016502530A1 (en) Pharmaceutical compositions comprising dgla and use of same
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
PH12017500459A1 (en) Azetidinyloxyphenylpyrrolidine compounds
MX2020009966A (es) Formas de dosificacion y usos terapeuticos de la l-4-cloro quinurenina.
EP3151826A4 (en) Omega-3 compositions, dosage forms, and methods of use
RU2014154366A (ru) Применение пробиотического штамма микроорганизма enterococcus faecium l3 для лечения нейродегенеративных заболеваний
PH12020500472A1 (en) Autotaxin inhibitor compounds
MX2016010967A (es) Nuevas composiciones para tratar lesiones neuronales mecanicas.
GEAP201814335A (en) Pharmaceutical composition for the prevention and treatment of diseases associated with elevated inducible nitric oxide synthase
UA96859U (uk) Застосування рослинного збору "дента-фіт" для лікування запальних захворювань пародонта
HK1234671A1 (en) Omega-3 compositions, dosage forms, and methods of use
UA92247U (ru) ПРИМЕНЕНИЕ МЕТИЛОВОГО ЭСТЕРА 5-МЕТИЛ-4-ОКСО-3,4-ДИГИДРОТИЕНО[2,3-d]ПИРИМИДИН-6-КАРБОНОВОЙ КИСЛОТЫ КАК АНАЛЬГЕТИЧЕСКОГО И ПРОТИВОВОСПАЛИТЕЛЬНОГО СРЕДСТВА